Importantly, since perturbation of the GABA-mediated inhibitory system is implicated in the pathogenesis of not only epilepsy but also several neuropsychiatric disorders, such as autism, schizophrenia, depression, and anxiety, we suggest that transcriptional control of GADs may serve as a potential therapy for the restoration of impaired GABAergic inhibitory functions [30]. Here, GRAP2 is linked to schizophrenia.